People · Operator

Kyle Chan, PhD

Named in public records as an officer, director or promoter · active 2014–2015 · Biotechnology

1
Companies
3
Filings
$93.8M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Biotheryx, Inc.BiotechnologySeries C$93.8M$2.7B2014
Operator network

Kyle Chan, PhD at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Robert F. Williamson · 2 companies · 1 sharedRobert F. William…Christopher A. Devine · 1 companies · 1 sharedChristopher A. De…David I. Stirling · 1 companies · 1 sharedDavid I. StirlingDavid Stirling, PhD · 1 companies · 1 sharedDavid Stirling, P…Dung W.H. Thai · 1 companies · 1 sharedDung W.H. ThaiFrank Mercurio, PhD · 1 companies · 1 sharedFrank Mercurio, P…Frank W.H. Mercurio · 1 companies · 1 sharedFrank W.H. Mercur…Jack A. Noelke · 1 companies · 1 sharedJack A. NoelkeJaime A. Donadio · 1 companies · 1 sharedJaime A. DonadioKyle W.H. Chan · 1 companies · 1 sharedKyle W.H. ChanLawrence Zaslow · 1 companies · 1 sharedLawrence ZaslowLouis DeGennaro, PhD · 1 companies · 1 sharedLouis DeGennaro, …Louis W.H. DeGennaro · 1 companies · 1 sharedLouis W.H. DeGenn…Biotheryx, Inc. · $93.8M raisedBiotheryx, Inc.Kyle Chan, PhDKP
Kyle Chan, PhD Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Kyle Chan, PhD on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Robert F. Williamson12
Lawrence Zaslow11
David Stirling, PhD11
Louis DeGennaro, PhD11
Kyle W.H. Chan11
Dung W.H. Thai11
Jack A. Noelke11
Christopher A. Devine11
Jaime A. Donadio11
Louis W.H. DeGennaro11
David I. Stirling11
Frank Mercurio, PhD11
Frank W.H. Mercurio11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.